Style | Citing Format |
---|---|
MLA | Keshavarzmotamed A, et al.. "Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy." Current Molecular Pharmacology, vol. 17, no. 1, 2024, pp. -. |
APA | Keshavarzmotamed A, Mousavi V, Masihipour N, Rahmati A, Dehmordi RM, Ghezelbash B, Alimohammadi M, Mafi A (2024). Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy. Current Molecular Pharmacology, 17(1), -. |
Chicago | Keshavarzmotamed A, Mousavi V, Masihipour N, Rahmati A, Dehmordi RM, Ghezelbash B, Alimohammadi M, Mafi A. "Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy." Current Molecular Pharmacology 17, no. 1 (2024): -. |
Harvard | Keshavarzmotamed A et al. (2024) 'Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy', Current Molecular Pharmacology, 17(1), pp. -. |
Vancouver | Keshavarzmotamed A, Mousavi V, Masihipour N, Rahmati A, Dehmordi RM, Ghezelbash B, et al.. Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy. Current Molecular Pharmacology. 2024;17(1):-. |
BibTex | @article{ author = {Keshavarzmotamed A and Mousavi V and Masihipour N and Rahmati A and Dehmordi RM and Ghezelbash B and Alimohammadi M and Mafi A}, title = {Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy}, journal = {Current Molecular Pharmacology}, volume = {17}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Keshavarzmotamed A AU - Mousavi V AU - Masihipour N AU - Rahmati A AU - Dehmordi RM AU - Ghezelbash B AU - Alimohammadi M AU - Mafi A TI - Regulating Mirnas Expression by Resveratrol: Novel Insights Based on Molecular Mechanism and Strategies for Cancer Therapy JO - Current Molecular Pharmacology VL - 17 IS - 1 SP - EP - PY - 2024 ER - |